External VNS Devices Market - Forecast(2024 - 2030)

External VNS Devices Market Overview

External VNS Devices Market size is estimated to reach $987 billion by 2027, growing at a CAGR of 13.4% during the forecast period 2022-2027. External VNS Devices depend on electrical signals that can pass by way of the skin and muscles of the neck without bringing about injury to the tissue. It must be sufficiently precise to access and curb the specific action of the nerve. Non-invasive or external vagus nerve stimulators are not implanted within the body. Instead, they are tiny being either hand-held devices that communicate electrical impulses by way of surface or skin contacts. These devices at times include an ear electrode that is able to stimulate specific nerve fibers through electric impulses, also termed neurostimulation. These devices are principally based on transcutaneous vagus nerve stimulation technology. gammaCore™ is a non-invasive vagus nerve stimulator that has been certified by the U.S. Food And Drug Administration (FDA). Electroconvulsive therapy (ECT) is a technique, performed under general anesthesia, in which tiny electric currents are passed by way of the brain, deliberately generating a short seizure. ECT seems to bring about alterations in brain chemistry that can expeditiously reverse symptoms of some mental health conditions. Investigations have examined the application of electroconvulsive therapy (ECT) in the important investigation of vagus nerve stimulation (VNS) for treatment-resistant depression. “Electroconvulsive therapy and VNS are not mutually exclusive”. They can be applied securely and efficiently either sequentially or simultaneously. Vagus nerve stimulation (VNS) is a rare epilepsy treatment in which a peripheral intervention is utilized to treat an ailment that is completely connected to pathological events happening inside the brain. Neuromodulation has become a surging trend in the treatment of headaches, specifically migraines. The accessible treatments involve the Cefaly external trigeminal nerve stimulation (e-TNS) device, ElectroCore’s gammaCore noninvasive vagus nerve stimulator (VNS), and the sTMS mini, a transcranial magnetic stimulation (TMS) unit by eNeura. More currently, non-invasive neuromodulation techniques have acquired considerable interest in Autonomic Nervous System (ANS) modulation. Norepinephrine (NE) is a neurotransmitter that has been connected with the clinical impacts of VNS by averting seizure development and by encouraging long-term plastic alterations that could revitalize the normal function of the brain circuitry. Articles have focused on healthy humans and how tVNS may be a convenient tool to further study the neuromodulation of cognitive processes connected to norepinephrine (NE), gamma-aminobutyric acid (GABA) and Acetylcholine (ACh), the three principal neurotransmitters aimed by VNS. One typical External VNS Devices industry application is in healthcare.

The surging financing of biotechnology and pharmaceutical firms in R&D and the development of neuromodulation devices like nVNS which is a noninvasive vagal nerve stimulator (Gammacore) is set to drive the External VNS Devices Market. The heightening product launches pertaining to non-invasive external vagus nerve stimulation devices and the strategic mergers and acquisitions are set to propel the growth of the External VNS Devices Industry during the forecast period 2022-2027. This represents the External VNS Devices Industry Outlook.

Report Coverage

The “External VNS Devices Market Report - Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the following segments in the External VNS Devices Market.

Key Takeaways

• Geographically, North America External VNS Devices Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the progressive technology and the increasing predominance of neurological ailments requiring application of electroconvulsive therapy in the North American region.
• External VNS Devices Market growth is being driven by the soaring development in technology and the launch of novel external VNS devices and neuromodulation treatments. However, larger fibers penetrating the brain are more probable to be the target of likely therapies and it is hard for an external device that cannot be linked to individual nerve fibers to spot these fibers and this is one of the major factors hampering the growth of External VNS Devices Market. 
• External VNS Devices Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the External VNS Devices Market report. 

External VNS Devices Market Segment Analysis – By Product Type:

The External VNS Devices Market based on product type can be further segmented into Non-Invasive Devices. The Non-Invasive Devices Segment held the largest External VNS Devices market share in 2021. This growth is owing to the surging application of non-invasive devices for the treatment of cluster headaches and migraines. gammaCore is a secure, efficient and effortless to apply treatment for COVID-19 and comes with “Emergency Use Authorization” to treat users with recognized or suspected COVID-19 and enduring decreased airflow. The soaring inclination of certain patients towards external VNS devices without undergoing surgery is further propelling the growth of the Non-Invasive Devices segment.

Furthermore, the Non-Invasive Devices segment is estimated to grow with the fastest CAGR of 13.9% during the forecast period 2022-2027 owing to the heightening application of external VNS devices attributed to numerous external VNS devices being hand-held devices together with application of neuromodulation treatments.

External VNS Devices Market Segment Analysis – By End User:

The External VNS Devices Market based on end user can be further segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCs) and Others. The Hospitals Segment held the largest External VNS Devices market share in 2021. This growth is owing to the surging application of neuromodulation treatments including non-invasive hand-held medical devices like gammaCore for treatment of migraines and as adjunctive therapy for seizures in hospital emergency departments. The heightening application of non-invasive devices like NEMOS Transcutaneous Vagus Nerve Stimulator in the treatment of drug-resistant epileptic patients, specifically with seizures for patients unwilling to undergo surgery in hospitals is further propelling the growth of this segment.

Furthermore, the Ambulatory Surgical Centers (ASCs) segment is estimated to grow with the fastest CAGR of 13.5% during the forecast period 2022-2027 owing to the extensive benefits provided by ambulatory surgical centers like offering an appropriate environment and cost effective services which are not as stressful as hospitals.

External VNS Devices Market Segment Analysis – By Geography:

The External VNS Devices Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America and Rest of the World. North America (External VNS Devices Market) held the largest External VNS Devices market share with 36% of the overall market in 2021. The growth of this region is owing to the increasing predominance of mental health issues and neurological ailments requiring the application of electroconvulsive therapy in the North American region. External VNS devices are not implanted within the human body. The surging expenditure on healthcare and the heightening government backing for R&D activities are further propelling the growth of the External VNS Devices Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR of 14.2% over the forecast period 2022-2027. This growth is owing to factors like the existence of rapidly developing healthcare technology and the surging application of electroconvulsive therapy for treatment of depression in the Asia-Pacific region. The huge population of patients and the soaring spending on healthcare are further fueling the progress of the External VNS Devices Market Share in the Asia-Pacific region. 

External VNS Devices Market Drivers

Surging Applications of External VNS Devices are Projected to Drive the Growth of External VNS Devices Market:

VNS devices act as an add-on therapy for mature grown-ups and children from 4 years, to treat focal or partial seizures that do not respond to seizure medicines like drug-resistant epilepsy or refractory epilepsy. Also, there are heightening applications of external VNS devices; For example, electroCore has developed gammaCore which is the drug-free solution for migraine and cluster headache. It treats and averts migraine and cluster headache with no pills, injections or drug-like side effects. The gammaCore SapphireTM is the earliest and only FDA cleared non-invasive device to treat and avert numerous kinds of headache pain through the vagus nerve. It is tiny, handheld and portable for fast and effortless treatments whenever and wherever required. For acute applications, gammaCore can be utilized for treatment and with a smaller number of 2 minute treatments, quick-acting and long-lasting pain alleviation may be experienced by patients. Treatment 3 times a day may be performed for greater headache free days and to go through life with reduced interruption. gammaCore provides safe, efficient and effortless treatment for migraine, cluster headache, Hemicrania Continua (HC) & Paroxysmal Hemicrania (PH) and comes with Emergency Use Authorization for COVID-19. The recommended treatment for applying gammaCore to avert migraine headache is providing oneself 3 treatments (morning, mid-day and night) including two successive 2-minute stimulations. These kinds of surging applications of External VNS Devices are therefore fueling the growth of the External VNS Devices Market during the forecast period 2022-2027.

Soaring Significance of Transcutaneous Vagus Nerve Stimulation (tVNS) is Expected to Boost the Growth of the External VNS Devices Industry:

Vagus Nerve Stimulation (VNS) therapy is a treatment for epilepsy patients. As per the Centers For Disease Control And Prevention (CDC), mental ailments are amidst the most typical health conditions in the U.S. and greater than 50% will be diagnosed with a mental ailment at a certain point in their lifetime with 1 in 5 Americans enduring a mental ailment in a given year. Transcutaneous vagus nerve stimulation—or, tVNS—is a pioneering therapy. Over ten years of research show that the vagus nerve has the potential to influence the mind and body in extensive ways. The vagus nerve effects the mood, the appetite, how well one sleeps, and even the cognition. tVNS excites the vagus nerve with an electric current. Investigations point that this stimulation causes a physiological chain reaction that enhances wellbeing. The human body includes two vagal nerves that run down the sides. Each vagus nerve is one of the basic pathways of the parasympathetic nervous system. A tVNS device is a transcutaneous vagus nerve stimulator. Similar to the initial VNS implant, a tVNS excites the vagus nerve with an electric current. However, contrary to the VNS implant, a tVNS stimulator is external. It is not required to implant it surgically. Instead, it excites the vagus nerve by way of points on the skin. The soaring significance of transcutaneous vagus nerve stimulation (tVNS) is therefore driving the growth of the External VNS Devices Industry during the forecast period 2022-2027.

External VNS Devices Market Challenges

Challenges of Transcutaneous Vagus Nerve Stimulation are Hampering the Growth of the External VNS Devices Market:

As per Centers For Disease Control And Prevention (CDC), 1 in 25 Americans resides with a severe mental ailment like schizophrenia, bipolar disorder or major depression. Investigations have been conducted to study the feasibility, security and efficiency of transcutaneous VNS in stable schizophrenia. tVNS is a non-invasive method that includes the utilization of electrical currents by way of surface electrodes at select locations, most typically aiming at the auricular branch of the vagus nerve (ABVN) and the cervical branch of the vagus nerve in the neck. Though it has been demonstrated that tVNS draws out hypo- and hyperactivation in different regions of the brain related with anxiety and mood regulation, the mechanism of action and affect of stimulation parameters on clinical outcomes stays predominantly hypothetical. Suppositions are broadly based on correlations between the neurobiology of the vagus nerve and its impacts on neural activity. However, tVNS has also been examined for numerous other ailments, inclusive of tinnitus, migraine and pain, by aiming at the vagus nerve at sites in both the ear and the neck. As majority of the described techniques differ in the parameters and protocols used, there is presently no firm proof on the optimal location for tVNS or the stimulation parameters that offer the greatest therapeutic impacts for a particular condition. These issues are thus hampering the growth of the External VNS Devices Market.

External VNS Devices Industry Outlook

Consistent innovations resulting in novel non-invasive device launches, technological advancements, acquisitions, geographical expansions and R&D activities are key strategies adopted by players in the External VNS Devices Market. The top 10 companies in the External VNS Devices Industry Outlook are:

1. electroCore
2. Parasym
3. TENS 7000
4. VITOS (tVNS Technologies)
5. AUVON
6. NURSAL
7. Belifu
8. Massage Therapy Concepts
9. HealthmateForever
10. Discount TENS

Recent Developments

• In January 2022, electroCore, Inc., a commercial-stage bioelectronic medicine firm, declared that its gammaCore™ nVNS device has accepted Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for the treatment of posttraumatic stress disorder (PTSD) after demonstrating a decrease of symptoms of PTSD by 31% in comparison with counterfeit. PTSD is a greatly extensive and crippling ailment with restricted certified treatment alternatives. As per the U.S. Department of Veterans Affairs National Center for PTSD, nearly 15 million mature grown-ups in the U.S. experience PTSD every year.
• In December 2021, electroCore, Inc., a commercial-stage bioelectronic medicine firm, offered an update on the ongoing clinical research to evaluate the potential of gammaCore (non-invasive vagal nerve stimulation; nVNS) to treat Post Traumatic Stress Disorder (“PTSD”). PTSD is a draining ailment caused by undergoing or observing a traumatic event that is increasingly typical. Nearly 15 million mature grown-ups in the U.S. will have PTSD during a given year and it is specifically concerning to the Military and Veteran’s Administration (VA).
• In April 2021, electroCore, Inc., a commercial-stage bioelectronic medicine firm, declared that Johns Hopkins University School of Medicine is beginning an investigator-initiated trial of non-invasive vagus nerve stimulation (nVNS) applying the Company’s proprietary gammaCore device to treat symptomatic exacerbation of nausea in patients with gastroparesis and related disorders (NCT04857281). Numerous gastrointestinal ailments can bring about nausea and vomiting, of which the most well-recognized is gastroparesis, a digestive ailment in which the stomach clears gradually. The symptoms of gastroparesis can range from gentle to serious, needing extended hospitalizations and interventions, and bringing about life-alarming complexities which can considerably influence the quality of life in affected individuals. This concludes the External VNS Devices Industry Outlook.

Related Reports

Human Insulin Market - Forecast(2022 - 2027)

Report Code: HCR 0477

Orthopedic Devices Market - Forecast(2022 - 2027)

Report Code: HCR 1228

Gynaecological Devices Market - Forecast(2022 - 2027)

Report Code: HCR 0034

For more Lifesciences and Healthcare Market reports, please click here